| Title |
Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells
|
|---|---|
| Published in |
OncoTargets and therapy, February 2015
|
| DOI | 10.2147/ott.s78358 |
| Pubmed ID | |
| Authors |
Alexandra Iulia Irimie, Cornelia Braicu, Oana Zanoaga, Valentina Pileczki, Claudia Gherman, Ioana Berindan-Neagoe, Radu Septimiu Campian |
| Abstract |
Epigallocatechin-3-gallate (EGCG) is the major bioactive component of green tea. Our experimental data indicated that EGCG treatment suppresses cell proliferation of SSC-4 human oral squamous cell carcinoma (OSCC), the effect being dose- and time-dependent. In parallel was observed the activation of apoptosis and autophagy, in response to EGCG exposure in SSC-4 cells. Treatment with EGCG activates the expression of the BAD, BAK, FAS, IGF1R, WNT11, and ZEB1 genes and inhibits CASP8, MYC, and TP53. All of these results suggest that EGCG has an excellent potential to become a therapeutic compound for patients with OSCC, by inducing tumor cell death via apoptosis and autophagy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 18% |
| Student > Master | 7 | 11% |
| Student > Bachelor | 7 | 11% |
| Researcher | 5 | 8% |
| Student > Postgraduate | 4 | 7% |
| Other | 9 | 15% |
| Unknown | 18 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 12 | 20% |
| Medicine and Dentistry | 9 | 15% |
| Agricultural and Biological Sciences | 5 | 8% |
| Chemistry | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Other | 4 | 7% |
| Unknown | 23 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2015.
All research outputs
#19,945,185
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#1,447
of 3,016 outputs
Outputs of similar age
#254,547
of 361,178 outputs
Outputs of similar age from OncoTargets and therapy
#13
of 18 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,178 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.